nct_id: NCT04943653
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2021-06-29'
study_start_date: '2021-06-08'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Paclitaxel'
long_title: Phase I,II Study of First Line Intraperitoneal Paclitaxel With Systemic
  Capecitabine and Oxaliplatin Combination Therapy in Patients With Advanced Gastric
  Cancer With Peritoneal Metastasis
last_updated: '2021-07-06'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Seoul St. Mary's Hospital
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 61
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- '1. Inclusion Criteria:'
- '* ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1'
- '* pathologically proven primary gastric adenocarcinoma'
- '* peritoneal metastasis confirmed by laparoscopy or diagnostic imaging'
- '* written informed consent'
- '* adequate function of important organs (within 14 days before registration)'
- "Absolute neutrophil count \u22651.5 x 10\\^9/L, Platelet \\>=100,000/mm3, Hemoglobin\
  \ \\>=8.0g/dL, Total bilirubin \\<= \u2264 2.0mg/dl or ULN(Upper Limit of Normal)\
  \ x 1.5, AST(aspartate aminotransferase) \\<=100IU/L(International Unit/Liter),\
  \ ALT(alanine transaminase) \\<=100IU/L, Creatinine clearance \u2265 50mL/min (milliliter/minute),"
- 'Exclude - 2. Exclusion Criteria:'
- Exclude - * other active concomitant malignancies
- Exclude - * HER2(human epidermal growth factor receptor 2) positive (Immunohistochemistry
  3+ or 2+ with in situ hybridization positive)
- Exclude - * no investigational anticancer therapy within 30 days prior to the first
  dose of study treatment
- Exclude - * recent (within 6 months) acute coronary syndrome, severe heart failure
  or severe pulmonary disease
- Exclude - * uncontrolled acute or chronic disease
- Exclude - * uncontrolled infection or inflammation
- Exclude - * uncontrolled psychiatric disorder or central neurologic disease
- Exclude - * not fully recovered from previous surgery
- Exclude - * prior anticancer therapy (chemotherapy, immunotherapy, radiation) within
  6 months
- Exclude - * intolerable to oral administration or a lack of physical integration
  of the upper gastrointestinal tract or with a malabsorption syndrome
- Exclude - * fertile males and females who are unwilling to use effective contraceptive
  methods.
- Exclude - * pregnancy, breast feeding or intention to become pregnant
- Exclude - * interstitial pneumonia or pulmonary fibrosis
- Exclude - * peripheral neuropathy with functional impairment
- Exclude - * hypersensitivity to paclitaxel, oxaliplatin, capecitabine, fluoropyrimidine
  or Cremophor EL.
- Exclude - * concomitant therapy with any substrate or inhibitor of Cytochrome P450
  2C8 or 3A4
- Exclude - * concomitant therapy with sorivudine or brivudine
- Exclude - * Dihydropyrimidine dehydrogenase (DPD) deficiency.
- Exclude - * current or recent (within the 7 days prior to enrollment) treatment
  of tegafur-gimeracil-oteracil potassium
short_title: Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal
  Metastasis
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Seoul St. Mary's Hospital
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: 'IPXELOX will investigate the safety, tolerability, and antitumor activity
  of intraperitoneal paclitaxel in combination with chemotherapy in patients with
  advanced gastric cancer with peritoneal metastasis.


  Study hypotheses: Intraperitoneal paclitaxel administered to subjects at the recommended
  phase 2 dose will show manageable safety and tolerability and anti-tumor efficacy
  with systemic capecitabine and oxaliplatin in advanced gastric cancer with peritoneal
  metastasis.'
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Intraperitoneal paclitaxel + XELOX
      arm_internal_id: 0
      arm_description: 'Intraperitoneal paclitaxel Day1, Day8 + \*XELOX


        \*XELOX ; Capecitabine 2000mg/m2/day(Day1-14) Oxaliplatin 100mg/m2 IV Day1
        q 3 weeks'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Peritoneal Serous Carcinoma
        - clinical:
            oncotree_primary_diagnosis: Esophagogastric Adenocarcinoma
        - clinical:
            oncotree_primary_diagnosis: Gastrointestinal Neuroendocrine Tumors of
              the Esophagus/Stomach
      - clinical:
          age_numerical: '>=20'
          her2_status: '!Positive'
          disease_status:
          - Metastatic
